Prulifloxacin. NAD-441A, NM 441, Quisnon.
D000818:Animals; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004148:Dioxolanes / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004347:Drug Interactions; D004751:Enteritis / Q000188:drug therapy; D024841:Fluoroquinolones; D006801:Humans; D008297:Male; D051379:Mice; D010879:Piperazines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011472:Prostatitis / Q000188:drug therapy; D015363:Quinolones / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012141:Respiratory Tract Infections / Q000188:drug therapy; D013530:Surgical Wound Infection / Q000188:drug therapy
D000890:Anti-Infective Agents; D004148:Dioxolanes; D024841:Fluoroquinolones; D010879:Piperazines; D015363:Quinolones; C074191:prulifloxacin